Coherus (CHRS) Q2 Revenue Jumps 10%
Coherus Oncology (NASDAQ:CHRS), a biotechnology company focused on developing and commercializing innovative immuno-oncology therapies, reported earnings for Q2 2025 on August 7, 2025. The results showed GAAP revenue reached $10.3 million, surpassing consensus expectations of $9.35 million (GAAP), a 10.2% outperformance in GAAP revenue, largely attributed to LOQTORZI’s expanding market presence. However, the company reported a non-GAAP loss per share of $(0.34), falling short of the $(0.22) analyst consensus (Non-GAAP). The quarter highlighted strong top-line growth, with GAAP net revenue of $10.3 million, ongoing momentum in LOQTORZI sales, and increased financial flexibility from recent asset sales, but continuing operating losses and dependence on a single oncology product remain key points for stakeholders.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Coherus Oncology is now a focused immuno-oncology company, following its divestment of earlier biosimilar franchises. The company’s current commercial engine is powered by LOQTORZI, its PD-1 immune checkpoint inhibitor, used for the treatment of nasopharyngeal carcinoma (NPC), a rare and aggressive cancer.
Source Fool.com
